Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 25,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Organ Transplantation
Interventions: RIPC (Remote Ischemic Preconditioning); Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 6 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Newark, New Jersey • San Antonio, Texas

Conditions: Barrett's Esophagus
Interventions: SECM Probe; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Tenofovir DF, Zidovudine, Stavudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 6
States / cities: Los Angeles, California • Fort Lauderdale, Florida • Jacksonville, Florida + 2 more

Conditions: Vestibular Disorder, Headache, Traumatic Brain Injury
Interventions: Osteopathic Manipulative Treatment; Other
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Mason, Michigan

Conditions: Renal Pelvis and Ureter Urothelial Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Pegfilgrastim, Therapeutic Conventional Surgery, Vinblastine Sulfate; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 258
States / cities: Kingman, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 197 more

Conditions: Tourniquet Placement, Wound Packing
Interventions: Simulation; Other
Lead sponsor: White Plains Hospital; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Timeline: 2019
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions: erlotinib hydrochloride, fluorouracil, leucovorin calcium, oxaliplatin, bevacizumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Immune Checkpoint Therapy
Interventions: Troponin surveillance, Standard of care; Diagnostic Test · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 980 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dermatology/Skin - Other
Interventions: VC Group; Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Foot Injury, Ankle Injury
Interventions: Saphenous Nerve Block; Procedure
Lead sponsor: Paul J. Juliano, M.D.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Obstetrical Complications, Labor and Delivery Complication, Cesarean Delivery
Interventions: Azithromycin Injection, Placebo, Standard of Care Preoperative antibiotics; Drug
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more

Conditions: Sexual Violence
Interventions: Brothers as Allies, Programming-as-Usual; Behavioral
Lead sponsor: New York State Department of Health; Government
Eligibility: 12 Years to 14 Years · Male only
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cervical Pre-cancer
Interventions: transvaginal digital colposcope (TVDC), Standard of care screening; Device · Other
Lead sponsor: Duke University; Other
Eligibility: 25 Years and older · Female only
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Intracerebral Hemorrhage
Interventions: Viz RECRUIT; Device
Lead sponsor: Viz.ai, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: Little Rock, Arkansas • Evanston, Illinois • Camden, New Jersey + 3 more

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Unresectable Melanoma
Interventions: Ipilimumab, Nivolumab, Lymph Node Assessment, Biospecimen Collection; Biological · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dental Caries
Interventions: Pre-Rotated (Group R), No pre-rotation; Other
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 2 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Cardiac Disease, Healing Surgical Wounds
Interventions: Study-required procedures include: tissue collection from device capsule, questionnaire collection, and photo collection; Other
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Clearwater, Florida • Tallahassee, Florida • Ridgewood, New Jersey + 3 more

Conditions: Erectile Dysfunction
Interventions: Nebivolol, Sugar Pill; Drug
Lead sponsor: Martin M. Miner, MD; Other
Eligibility: 25 Years to 65 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Providence, Rhode Island

Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Recurrent Adult Brain Tumor
Interventions: erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Bethesda, Maryland + 4 more

Conditions: Hemophilia
Interventions: Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC); Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year to 11 Years · Male only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 8
States / cities: Los Angeles, California • Orange, California • Torrance, California + 4 more

Conditions: Pain, Postoperative
Interventions: Fentanyl, Naltrexone; Drug
Lead sponsor: Incline Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Pancreatic Cancer
Interventions: Cetuximab, Pancreatic tumor vaccine, Cyclophosphamide; Drug · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Device Latency
Interventions: Placebo, Combination product of Aripiprazole + IEM + Sensor + MIND1 Application; Drug · Combination Product
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Graft-vs-Host Disease, GVHD
Interventions: Brentuximab Vedotin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Remote Ischemic Preconditioning in Neurological Death Organ Donors

Using Spectrally Encoded Confocal Microscopy (SECM) to Visualise the Esophagus Using an SECM Probe

Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Effectiveness of the Adding High Fidelity Simulation to the Bleeding Control Course in Regards to Proper Tourniquet Placement Amongst School Personnel

A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer

STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy

Animated Video Consultation for Reducing Pre-Operative Anxiety in Outpatient Dermatologic Surgery

Ideal Anatomic Location for Saphenous Nerve Blocks: A Prospective Clinical Evaluation

Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

Preventing Sexual Violence Among Middle School Boys With a Strengths-Based Curriculum

A See and Treat Paradigm for Cervical Pre-cancer

AI ENRICH - AI Detection of ICH

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

ETT Rotation During Nasal Fiberoptic Intubation

TYRX™ Pocket Health Study

Nebivolol Effects on Endothelial Function and Erectile Function

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Pharmacokinetic Characterization of the Active, Separated System With PK Controller (Fentanyl Iontophoretic Transdermal System, 40 Mcg Fentanyl Per Activation).

Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)